Regeneron Pharmaceuticals, Inc. REGN

NAS: REGN | ISIN: US75886F1075   8/10/2026
739,57 USD (-0,34%)
(-0,34%)   8/10/2026
Grafiek Regeneron Pharmaceuticals, Inc. Grafiek Regeneron Pharmaceuticals, Inc.
vrijdag 30 oktober 2026, 11:30
Kwartaalcijfers (3de kwartaal)

Regeneron Pharmaceuticals, Inc. in het nieuws

13 september 2026 · REGN INVESTOR DEADLINE TOMORROW: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit, Robbins Geller Rudman & Dowd LLP Announces · Persbericht

10 september 2026 · SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 14, 2026 in Regeneron Pharmaceuticals, Inc. Lawsuit - REGN · Persbericht

10 september 2026 · Faruqi & Faruqi, LLP Urges Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) Investors to Seek Counsel Before the September 14, 2026 Lead Plaintiff Deadline in the Securities Class Action · Persbericht

10 september 2026 · REGN MONDAY DEADLINE: Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit · Persbericht

9 september 2026 · Levi & Korsinsky Reminds Regeneron Pharmaceuticals Investors of the Pending Class Action Lawsuit With a Lead Plaintiff Deadline of September 14, 2026 - REGN · Persbericht

1 september 2026 · INVESTOR DEADLINE: Regeneron Pharmaceuticals, Inc. (REGN) Investors with Substantial Losses Have Opportunity to Lead the Regeneron Class Action Lawsuit Before September 14, 2026 Deadline · Persbericht

28 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: Securities Fraud Class Action Filed, Contact Hagens Berman Before September 14, 2026 Lead Plaintiff Deadline · Persbericht

27 augustus 2026 · REGN DEADLINE: SueWallSt Reminds Regeneron Pharmaceuticals, Inc. Investors of Upcoming Securities Class Action Deadline · Persbericht

27 augustus 2026 · Regeneron Pharmaceuticals, Inc. (REGN) Investors: September 14, 2026 Lead Plaintiff Deadline in Class Action Lawsuit · Persbericht

24 augustus 2026 · Regeneron Pharmaceuticals, Inc. Investors with Substantial Losses Have Opportunity to Lead Regeneron Class Action Lawsuit - Hagens Berman Sobol Shapiro LLP · Persbericht

Profiel Regeneron Pharmaceuticals, Inc.

Biotechnologie
Fabricage van farmaceutische preparaten
Gezondheidstechnologie
Productie

Website: www.regeneron.com

Hoofdzetel: Tarrytown, New York vlag Verenigde Staten

Mijn selecties